Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.61 USD
+0.07 (2.76%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Poseida Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -123.43 | -64.00 | -124.97 | -129.78 | -86.53 |
Depreciation/Amortization & Depletion | -1.96 | 4.24 | 5.32 | 3.22 | 2.05 |
Net Change from Assets/Liabilities | 14.08 | 13.72 | 20.17 | 5.62 | 9.47 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 19.15 | 19.27 | -3.06 | 7.61 | 10.62 |
Net Cash From Operating Activities | -92.17 | -26.77 | -102.54 | -113.33 | -64.39 |
Property & Equipment | -3.07 | -3.91 | -2.62 | -16.91 | -5.16 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 42.20 | -199.42 | 225.00 | -187.52 | -37.44 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 39.13 | -203.33 | 222.38 | -204.43 | -42.59 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 16.62 | 76.61 | 2.52 | 314.27 | 154.42 |
Issuance (Repayment) of Debt | 0.00 | 30.00 | 0.00 | 0.00 | 10.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.49 | -1.45 | 0.00 | -0.33 | -0.05 |
Net Cash from Financing Activities | 16.13 | 105.16 | 2.52 | 313.94 | 164.37 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -36.91 | -124.95 | 122.36 | -3.82 | 57.39 |
Cash at Beginning of Period | 81.38 | 206.33 | 83.97 | 87.78 | 30.40 |
Cash at End of Period | 44.47 | 81.38 | 206.33 | 83.97 | 87.78 |
Diluted Net EPS | -1.37 | -0.89 | -2.01 | -3.61 | -6.86 |
Fiscal Year End for Poseida Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -55.65 | -24.27 | -123.43 | -98.08 | -66.30 |
Depreciation/Amortization & Depletion | -0.26 | -0.25 | -1.96 | -1.47 | -1.15 |
Net Change from Assets/Liabilities | 66.21 | 4.00 | 14.08 | 22.04 | -16.81 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.01 | 5.38 | 19.15 | 14.08 | 12.96 |
Net Cash From Operating Activities | 23.32 | -15.14 | -92.17 | -63.42 | -71.31 |
Property & Equipment | -1.15 | -0.13 | -3.07 | -2.76 | -1.97 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -36.05 | 24.13 | 42.20 | -5.82 | 40.63 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -37.20 | 24.00 | 39.13 | -8.58 | 38.66 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.55 | 0.55 | 16.62 | 16.62 | 1.68 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.59 | -0.59 | -0.49 | -0.49 | -0.49 |
Net Cash from Financing Activities | -0.04 | -0.04 | 16.13 | 16.13 | 1.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -13.93 | 8.83 | -36.91 | -55.88 | -31.47 |
Cash at Beginning of Period | 44.47 | 44.47 | 81.38 | 81.38 | 81.38 |
Cash at End of Period | 30.55 | 53.30 | 44.47 | 25.50 | 49.91 |
Diluted Net EPS | -0.32 | -0.25 | -0.25 | -0.35 | -0.32 |